AI biotech is compelling right now because it sits where two powerful market demands meet: drug developers want to shorten discovery timelines, and they also need better hit rates in a business where R&D is expensive and clinical failure is common. Investors are increasingly separating companies that simply talk about AI from those that can tie it to real platforms, commercial products, collaboration economics, or measurable operating progress. That distinction matters more in 2026 as capital remains selective across healthcare.
The opportunity spans several layers of the value chain. Some companies are AI-native drug discovery platforms, some sell software and computational tools into pharma, some monetize proprietary biological or diagnostic datasets, and others use AI to improve pipeline productivity in commercial biotech. A useful proof point for the theme is that Schrödinger reported 2025 total revenue of $255.9 million, including $199.5 million of software revenue, showing that AI-enabled biotech can already produce meaningful commercial revenue rather than only preclinical promise.
This list ranks seven AI biotech stocks in countdown order from #7 to #1 based on overall investment quality, not just narrative appeal. That means the companies near the top generally combine stronger business models, better financial profiles, and more credible commercialization paths, while lower-ranked names may still be interesting but carry materially higher execution risk.
For this screen, we focused on US-listed companies tied to the AI biotech theme with market capitalizations above $500 million, then ranked them by investment quality using our composite metrics, financial performance, growth trends, profitability, and analyst positioning. Because this is a countdown, the most attractive name on this framework appears last at #1. The goal is not to find the most speculative story, but to identify the companies with the best mix of AI relevance, commercial traction, and operating strength heading into June 2026.
What they do. The company is a clinical-stage genome editing biotech built around a proprietary CRISPR-based gene editing platform. Its lead program is EDIT-401 for hyperlipidemia, and it is also developing therapies for sickle cell disease, transfusion-dependent beta thalassemia, and other in vivo gene editing applications, with a research collaboration with Juno Therapeutics in cell therapies.
Why it fits. Editas makes the list because AI biotech is not only about software vendors; it also includes platform biotechs that use advanced computational approaches to improve how complex therapies are designed and prioritized. But compared with higher-ranked names here, Editas is much more dependent on clinical-stage execution than on already visible AI-linked commercial revenue.
Numbers that matter. Revenue is just $38.7 million, while EBITDA is negative $85.2 million and profit margin is negative 2.8159. Revenue declined 39.2% year over year, and trailing EPS is negative $1.14, though next-year EPS is estimated at negative $0.9365. Profitability is weak across the board, with ROE at negative 3.2607, ROA at negative 0.2695, gross margin at negative 109.2%, operating margin at negative 8.8319, and net margin at negative 2.8159.
Recent momentum. Editas missed in its most recent reported quarter, posting EPS of negative $0.26 versus an estimate of negative $0.24, an 8.3% miss, although it beat by 73.9% in February 2026 and has beaten in 4 of its last 7 reported quarters. Analyst sentiment remains cautious, with 1 Buy, 8 Holds, and 2 Sells, which fits its lower ranking on this list.
Market cap: $1.8B · Quality grade: C · Analyst consensus: Hold (avg target $6.64)
What they do. The company is a clinical-stage biotechnology platform that integrates biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Its pipeline includes REC-4881, REC-617, REC-1245, REC-3565, and REC-4539, and it also has collaborations with Roche & Genentech, Sanofi, Bayer, Tempus, and Takeda.
Why it fits. Recursion is one of the more direct AI biotech platform stories in the market because its whole model is built around decoding biology and chemistry at scale. It also fits the current theme context especially well because the company highlighted a 2025 milestone from Roche/Genentech tied to its platform, reinforcing that its AI stack can translate into collaboration economics rather than just internal discovery claims.
Numbers that matter. Revenue is $66.4 million against negative EBITDA of $501.2 million, underscoring how early the business still is relative to its cost base. Revenue fell 56.1% year over year, while trailing EPS is negative $1.16 and next-year EPS is estimated at negative $0.8788. Profitability remains deeply negative, with ROE at negative 0.5716, ROA at negative 0.2766, gross margin at negative 645.6%, and operating margin at negative 19.8555.
Recent momentum. Operationally, recent earnings have been somewhat better than feared: Recursion beat estimates in the last three reported quarters, including a 15.4% beat in May 2026 and a 30.0% beat in February 2026, and it has beaten in 4 of its last 7 reported quarters. Even so, analyst positioning is restrained, with 1 Buy and 6 Holds, reflecting interest in the platform but caution on the financial profile.
What they do. The company discovers and develops antibody-based medicines, combining its platform capabilities with internal programs and partnerships. Lead assets include ABCL635 in Phase 2 for vasomotor symptoms and ABCL575 in Phase 1 for T-cell-mediated autoimmune conditions, while its collaboration roster includes Eli Lilly, AbbVie, and Biogen.
Why it fits. Abcellera belongs in AI biotech because antibody discovery is a data-rich process where platform efficiency and candidate selection matter enormously. Its mix of internal development and partnered discovery gives it exposure to the same structural trend driving the theme: pharma companies paying for better discovery productivity and access to differentiated biological platforms.
Numbers that matter. Revenue was $79.2 million, up 96.3% year over year, one of the stronger top-line growth rates on this list. Earnings growth year over year was 45.9%, though the company is still unprofitable, with profit margin at negative 1.8174, EBITDA at negative $188.3 million, ROE at negative 0.1468, ROA at negative 0.0999, gross margin at negative 135.9%, and operating margin at negative 6.9175. Forward P/E is listed at 27.5482, but trailing earnings remain negative, so investors are still underwriting future execution.
Recent momentum. Abcellera has posted two strong recent earnings beats, with EPS of negative $0.14 versus negative $0.20 in May 2026, a 30.0% beat, and negative $0.03 versus negative $0.144 in February 2026, a 79.2% beat. It has beaten in 4 of its last 7 reported quarters, and analyst sentiment is constructive, with 2 Buys and 1 Hold.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. The company develops a physics-based computational platform used for molecular discovery across life sciences and materials science. Its business is split between Software, which sells computational tools, and Drug Discovery, which builds internal and partnered programs, including a research collaboration and license agreement with Novartis Pharma.
Why it fits. Schrödinger is one of the clearest examples of AI-enabled biotech generating real commercial revenue today. In the current market backdrop, that matters: the company reported 2025 total revenue of $255.9 million, including $199.5 million of software revenue, which supports the idea that AI biotech can monetize through recurring software relationships as well as therapeutic upside.
Numbers that matter. Revenue stands at $254.9 million, making Schrödinger one of the more substantial commercial businesses in this group. Gross margin is a healthy 55.3%, but the company is still loss-making, with operating margin at negative 0.8329, net margin at negative 0.406, EBITDA at negative $158.9 million, ROE at negative 0.3012, and ROA at negative 0.1496. Revenue declined 1.6% year over year, and next-year EPS is estimated at negative $1.565 versus trailing EPS of negative $1.40.
Recent momentum. Schrödinger missed in May 2026, reporting EPS of negative $0.62 against an estimate of negative $0.57, an 8.8% miss, but it had beaten in three of the prior four quarters and has beaten in 4 of its last 7 reported quarters overall. Analyst coverage is limited in the supplied data, with 2 Holds and an average target of $20.875, suggesting tempered but still constructive expectations.
What they do. The company is a precision oncology and diagnostics platform offering blood and tissue tests, software, and data products. Its portfolio includes Guardant360 CDx, Guardant360 Liquid, Guardant Reveal, Guardant360 Tissue, Shield for colorectal cancer screening, and biopharma-facing products such as GuardantINFORM, GuardantConnect, and the Smart Platform.
Why it fits. Guardant fits the AI biotech theme because it monetizes large-scale molecular data, diagnostics, and software in ways that support both providers and drug developers. This is exactly the kind of business model investors are rewarding in the space: proprietary datasets, clinically embedded testing, and tools that can improve patient stratification, biomarker discovery, and trial matching.
Numbers that matter. Revenue is $1.08 billion, making Guardant one of the most scaled names on the list, and revenue grew 48.3% year over year. Gross margin is 64.9%, but profitability is still negative, with operating margin at negative 0.4023, net margin at negative 0.401, EBITDA at negative $408.2 million, and ROA at negative 0.1715. Trailing EPS is negative $3.40, but next-year EPS is estimated at negative $0.5703, implying a major expected improvement in earnings power.
Recent momentum. Guardant has built strong earnings momentum, beating estimates in each of its last five reported quarters, including a 5.0% beat in May 2026 and a 35.5% beat in February 2026. Analyst sentiment is also favorable, with 6 Buys and 3 Holds, which helps explain why it ranks near the top despite still-negative margins.
Pick #2Subscribers only
Subscribers see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This ranking started with US-listed stocks tied to the AI biotech theme and a market capitalization threshold above $500 million, then narrowed the field using primary-source financial data, analyst consensus, earnings execution, and our composite quality grade. We emphasized investment quality over pure upside potential, so profitability, revenue scale, growth durability, and consistency of recent results mattered more than narrative alone. The list is presented in countdown format from #7 to #1, with the top pick revealed last. Because these articles refresh monthly, the ranking can change as companies report earnings, update guidance, or improve commercialization traction.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
